Coastar Therapeutics has developed an innovative technology known as ENHEnS™ that addresses significant challenges in cancer immunotherapy and gene therapy. The primary issue these therapies face is the immune system's ability to identify and clear biological payloads, such as DNA, mRNA, and therapeutic viruses, before they can effectively target and treat diseases. Coastar's solution involves a proprietary cell nano-membrane coating that protects these biological payloads from immune detection. By utilizing a layer of cell membrane, which contains self-identifying proteins, the coated payloads can evade the immune system, allowing for more effective delivery to tumors and other disease sites.

The advantages of Coastar's cell membrane coating technology are substantial. It enhances the efficacy of therapies by ensuring a higher concentration of payloads remains in circulation, thereby increasing the likelihood of successful treatment outcomes. Additionally, this technology allows for the systemic delivery of payloads to previously hard-to-reach areas, such as metastatic tumors, while minimizing toxicity and reducing costs associated with treatment. Overall, Coastar Therapeutics' ENHEnS™ technology represents a significant advancement in the field of cancer treatment, offering hope for improved therapeutic options for patients worldwide.

United States

Coastar Therapeutics is a pre-clinical biotech company developing biological payload delivery technologies for cancer immunotherapy and gene therapies.  Our proprietary ENHEnS technology can be used to coat biological payloads with cell membranes, which help them evade recognition and clearance by the immune system and be successfully delivered to tumor or other disease sites.

Coastar Therapeutics

Company Details